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hat to Anticipate From
ulse Pressure Amplification*
heodore G. Papaioannou, PHD,†
thanase D. Protogerou, MD,‡
hristodoulos Stefanadis, MD†
thens, Greece
he blood pressure (BP) wave is gradually distorted in terms
f shape as it travels from the central elastic arteries to the
uscular conduit arteries (1). This is a physiological phe-
omenon, associated with the fact that BP is a periodic
scillating wave that is transmitted and reflected within a
onuniform visco-elastic arterial bed. As a consequence, in
ealthy subjects, the amplitude (pulse pressure [PP]) of the
ressure wave increases gradually from the aorta/carotid
rteries to the brachial/radial arteries yet without any addi-
ional energy input in the arterial system, because the mean
rterial pressure (MAP) as well as the diastolic blood
ressure remain almost unchanged between these sites.
herefore, this phenomenon, known as “PP amplification,”
s attributed mainly to the gradual increase of the systolic
lood pressure (SBP). Several clinical implications regard-
ng optimal cardiovascular (CV) risk stratification and
reatment might arise due to the disparity of brachial and
entral PP (1).
See page 1032
The assessment of PP amplification requires measure-
ent/estimation of both peripheral and central PP. In the
urrent issue of the Journal, Benetos et al. (2) generated a
tatistical model to predict central PP from peripheral PP
nd classical CV risk factors. This model was based on data
erived from a population (n  834) referred to a special-
zed center for the management of CV disease, who
nderwent carotid BP estimation by using a validated
oninvasive methodology (direct carotid tonometry) (3).
his model was then applied in a large population of
25,151 subjects who underwent a health check-up, to
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Biomedical Engineering Unit, First Department of Cardiology, Hip-
ocration Hospital, Athens, Greece; and the ‡Hypertension Center, Third Depart-t
ent of Medicine, Sotiria Hospital, Medical School, National and Kapodistrian
niversity of Athens, Athens, Greece.stimate central PP and PP amplification and to investigate
heir association with mortality after 10 years of follow up.
he authors showed that PP amplification is an indepen-
ent predictor of mortality, at least as good as brachial and
entral PP or even better.
Herein, we will comment on the mechanics and patho-
hysiology of PP amplification, its clinical relevance, the
ovelty of the present outcome, as well as the strengths and
eaknesses of this study (2).
efinition and Clinical Relevance
f PP Amplification
ulse pressure amplification has been expressed by several
ormulas in the past. Most commonly, it is defined by the
atio PP2/PP1 between the distal site (PP2) (e.g., radial
rtery) and the proximal site (PP1) (e.g., aorta) (1). Alter-
atively, it can be expressed as the difference (in mm Hg)
P2  PP1 (1) or the ratio of (PP2  PP1)/PP1 (4). All
hese formulas might provide equivalent principal results
1,4,5); however, whether they are identical on the basis of
linical impact has to be further evaluated.
From a physiological point of view, for a given brachial
P, the lower the central PP the more beneficial the effect
n the CV system, because the heart and the aorta confront
ower pulsatile load (i.e., the higher the absolute difference
mm Hg] of PP amplification the better). Additionally, the
bsolute value of PP amplification decreases with age
1,4,5). Therefore, it seems more appropriate to express PP
mplification as PP2/PP1 (e.g., 80/60 mm Hg  1.33) (1)
ather than PP1/PP2 (e.g., 60/80 mm Hg  0.75) (2),
ecause the former formula integrates the 2 aforementioned
eatures. Herein, PP amplification will be defined as the
atio PP2/PP1.
Given the mounting evidence from studies showing that
entral, more than peripheral BP, is associated with target
rgan damage and potentially with CV risk (6), the disparity
etween central and peripheral PP (usually ranging from 5 to
0 mm Hg) has important clinical implications regarding
ptimal BP-associated CV risk stratification and treatment.
he BP-associated CV risk might be substantially over- or
nder-estimated when classified according to conventional
rachial BP measurements based on international guidelines
lassification due to a considerable overlap in aortic SBP
etween the discrete categories (5). Second, it is proven that
ot all classes of antihypertensive drugs have similar effect on
P amplification (7). Drugs with vasodilating effects increase
P amplification when compared with beta-blockers (7).
Supporting evidence on the clinical relevance of PP
mplification has been so far provided by 2 small prospective
tudies. In end-stage renal disease, low PP amplification but
ot brachial PP was an independent predictor of all cause
nd CV mortality (8), superior to carotid PP. In another
tudy evaluating untreated subjects with essential hyperten-
ion (9), regression of left ventricular mass index after
reatment was independently associated with the increase of
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March 9, 2010:1038–40 Pulse Pressure AmplificationP amplification but not with the reduction in brachial PP.
enetos et al. (2) showed for the first time in a large
pidemiological study that PP amplification is a predictor of
ll-cause as well as CV mortality, independently from
lassical CV risk factors.
echanics and Pathophysiology of PP Amplification
ross-sectional observational data in healthy subjects from
he ACCT (Anglo-Cardiff Collaborative Trial) (5) and the
sklepios Study (4) have shown that PP amplification is
odulated by vascular properties (large artery stiffness,
eripheral resistance, and mainly pressure wave reflections)
s well as by heart rate. The mechanism by which these
arameters affect the PP amplification is largely related to
he “timing–synchronization” of the forward and backward
reflected) pressure waves. The closer the BP is measured to
he reflections sites (i.e., further in the periphery), the earlier
he forward (ejected from the left ventricle) and the back-
ard (reflected at the peripheral reflection sites) travelling
aves will be coupled, enhancing the peak SBP (4). Clas-
ical nonmodifiable (i.e., age, sex) and modifiable (i.e.,
ypertension, diabetes mellitus, hypercholesterolemia,
moking) CV risk factors or established CV disease are also
ssociated with reduced PP amplification in observational
tudies (1,5). These factors act by accelerating “normal
ascular aging,” which is per se the main modulator of large
rtery stiffness and wave reflections.
From this point of view, PP amplification could be
onsidered as a mechanical biomarker of CV disease and
isk, as suggested by Benetos et al. (2), integrating CV risk
actors as well as global arterial properties. The available
ata imply that PP amplification is not just a mathematical
xpression but “carries” additional physiological informa-
ion, potentially above that of central and peripheral PP
lone. However, any new efficient biomarker should be easy
n application, useful for detection and prognosis as well as
or guiding treatment, but also it should provide comple-
entary and independent information compared with ex-
sting biomarkers. In this respect, the current data on PP
mplification are very limited.
pidemiology Versus Daily Clinical Practice
here is important intraindividual and interindividual vari-
tion of PP amplification (1,5). Invasive and noninvasive
tudies have shown that the gradient between central and
eripheral PP might change significantly under the acute or
hronic effect of vasoactive substances, drugs, or common
aily consumed beverages (1) and of course due to vascular
ging (4,5). Therefore, a statistical approach for the assess-
ent of central hemodynamic status is of limited value in
linical practice yet important for the understanding of
rterial mechanics from large epidemiological studies.
Moreover, the generalized application of any regression
odel is limited by the unavoidable differences between thetudied population and the “targeted” population. In theresent study the target population was younger with lower
urden of CV risk factors than the one used to generate the
tatistical model. The model generated in this study ex-
lained 86% of the variability of central PP. However,
lassical CV risk factors explained only up to 3% of central
P variance, whereas glucose was the only modifiable CV
isk factor in the model. Therefore, it could be speculated
hat direct instead of statistical assessment of PP amplifica-
ion might generate different results with a potential greater
rognostic significance.
Finally, it is important to clarify the effect of the steady
omponent of BP (i.e., MAP) in order to assess the
ndependent net effect of PP amplification on CV disease;
deally this requires direct assessment of MAP and PP
mplification.
erspectives
ulse pressure amplification is a physiological phenomenon
ith clinical implications. The need to noninvasively assess
entral PP is the major drawback. The available methods
ave several limitations (3); the cardinal one concerns the
eed for calibrating central pressure waveforms with non-
nvasively acquired peripheral BP or/and the use of mathe-
atical transformation models. The expression of PP am-
lification as a ratio of peripheral to central PP is potentially
ess dependent on calibration errors due to inaccuracies in
he measurement of diastolic blood pressure, as suggested by
he authors, which might be considered as an advantage of
his “biomarker.” Most importantly, the additional effort
nd cost to assess central hemodynamic parameters in
elected populations must be justified by clear data derived
rom clinical trials, currently lacking, demonstrating the
uperiority of these parameters over the conventional bra-
hial cuff BPs. The anticipation of optimal BP-associated
V risk stratification and treatment, on the basis of central
emodynamic status is physiologically relevant; yet, it might
urn into “Great Expectations” if further biomedical inno-
ation is not achieved in order to increase accuracy and
acilitate its application in clinical practice.
eprint requests and correspondence: Dr. Theodore G. Papa-
oannou, First Department of Cardiology, Biomedical Engineer-
ng Unit, Hippocration Hospital, 114 Vas. Sophias Avenue,
thens 115 28, Greece. E-mail: theopap@mail.ntua.gr.
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